secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001140361-26-018667
Event type: regulatory
Sentiment:  positive
Materiality: 0.78
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics receives FDA approval to expand ASCENIV label to pediatric patients 2 years+
--------------------------------------------------------------------------------

- FDA approved label expansion for ASCENIV to include pediatric primary humoral immunodeficiency patients aged 2 years and older.
- Previously approved only for patients 12 years and older; approval fulfills post-marketing pediatric assessment commitment.
- CEO Adam Grossman: expanded label allows addressing treatment needs of younger PI patients earlier in their treatment journey.
- COO Kaitlin Kestenberg highlighted collaboration with PI community and families; approval reflects strong clinical execution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126018667/0001140361-26-018667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126018667/ef20072196_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-018667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer